Merck’s New RSV Vaccine for Infants Enters Competitive Market
Merck’s newly FDA-approved RSV vaccine for infants enters a competitive market, challenging Sanofi and AstraZeneca’s Beyfortus. This breakthrough offers hope for protecting babies from severe respiratory illness, intensifying the race for innovative pediatric solutions.

